Holen Sie sich die Stockscreener-App
68.78
0.30%
-0.21
Handel nachbörslich:
69.20
0.42
+0.61%
Schlusskurs vom Vortag:
$68.99
Offen:
$69.81
24-Stunden-Volumen:
2.12M
Relative Volume:
0.80
Marktkapitalisierung:
$13.33B
Einnahmen:
$502.08M
Nettoeinkommen (Verlust:
$-732.94M
KGV:
-18.18
EPS:
-3.7842
Netto-Cashflow:
$-455.50M
1W Leistung:
-1.33%
1M Leistung:
-5.97%
6M Leistung:
+9.77%
1J Leistung:
+79.96%
1-Tages-Spanne:
$67.48
$70.42
1-Wochen-Bereich:
$67.48
$72.49
52-Wochen-Spanne:
$31.77
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
68.78 | 13.37B | 502.08M | -732.94M | -455.50M | -3.7842 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-03-10 | Eingeleitet | William Blair | Outperform |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-11 | Eingeleitet | Bernstein | Outperform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio to present encaleret data at endocrinology congress By Investing.com - Investing.com South Africa
BridgeBio Pharma to Present Phase 3 Infigratinib Achondroplasia Trial Results at ECE 2026, Focusing on Annualized Growth Velocity in Children Aged 3-11 - geneonline.com
MSN Money - MSN
BridgeBio to unveil Phase 3 rare-disease trial results in Prague - Stock Titan
BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) - MSN
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE - Yahoo Finance
BBIO SEC FilingsBridgebio Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity - Stock Titan
Achondroplasia Pipeline Expands as 15+ Pharma Companies - openPR.com
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026 - The Manila Times
New heart failure data on BridgeBio drug lands late-breaking ESC slot - Stock Titan
William Blair Initiates BridgeBio Pharma(BBIO.US) With Buy Rating - Moomoo
BridgeBio Pharma Inc. (BBIO): Billionaire Tom Steyer Admires Upside Potential of This Stock - Insider Monkey
BridgeBio gains amid report of settlement in Pfizer Vyndamax patent dispute - MSN
Vanguard Group Inc. Increases Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio (BBIO) Q2 2025 Earnings Transcript - AOL.com
(BBIO) Volatility Zones as Tactical Triggers - Stock Traders Daily
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Truist Financial Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $102 - Moomoo
Truist Financial Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET - The Manila Times
After the bell: BridgeBio schedules Q1 results and program update - Stock Titan
Is Attruby’s Accelerating Launch and Star-Studded Awareness Campaign Altering The Investment Case For BridgeBio Pharma (BBIO)? - Yahoo Finance
The Escalator: BridgeBio Oncology Therapeutics, Haleon, AstraZeneca and more - Medical Marketing and Media
BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore (NASDAQ:BBIO) - Seeking Alpha
BridgeBio rises after late-stage trial win for dwarfism therapy - MSN
BridgeBio Pharma Is Maintained at Buy by Truist Securities - Moomoo
BridgeBio earnings on deck: Can Attruby sustain rapid growth? By Investing.com - Investing.com South Africa
BridgeBio earnings on deck: Can Attruby sustain rapid growth? - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Wave Life Sciences (WVE) - The Globe and Mail
BBIO Maintained by Truist Securities -- Price Target Raised to $102 - GuruFocus
Truist Financial Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
BBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright reiterates BridgeBio Pharma stock rating on stable Vyndamax outlook - Investing.com Canada
BridgeBio Pharma, Inc. $BBIO Holdings Lifted by Moody Aldrich Partners LLC - MarketBeat
HC Wainwright Predicts Weaker Earnings for BridgeBio Pharma - MarketBeat
Pictet Asset Management Holding SA Has $96.96 Million Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Teachers Retirement System of The State of Kentucky Buys 17,343 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio launches ATTR-CM awareness campaign with Morgan Freeman By Investing.com - Investing.com South Africa
BridgeBio launches ATTR-CM awareness campaign with Morgan Freeman - Investing.com UK
BofA raises BridgeBio Pharma stock price target on Pfizer settlement clarity - Investing.com Canada
BridgeBio Oncology (Nasdaq: BBOT) details 2026 virtual meeting, board elections and auditor - Stock Titan
Raymond James reiterates BridgeBio stock rating on Vyndamax settlement By Investing.com - Investing.com Canada
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $106 - Moomoo
BBIO Reiterated by Mizuho -- Price Target Maintained at $106 - GuruFocus
Barclays sees Pfizer IP case progress as positive for BridgeBio stock - Investing.com Canada
Pfizer deals extend patent life for a top-selling rare disease drug - BioPharma Dive
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):